Evidence map›Paper›PMID 42773087›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Research satisfaction among participants in a preclinical Alzheimer's disease trial.

Marina Ritchie, Kedir Hussen, Oliver Langford, Michael C Donohue, Mary Sano, Joshua D Grill, Paul Aisen, Reisa Sperling, Rema Raman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marina RitchieEpstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Kedir HussenEpstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Oliver LangfordEpstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Michael C DonohueEpstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Mary SanoIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Joshua D GrillUniversity of California, Irvine, Irvine, California, USA.
Paul AisenEpstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Reisa SperlingCenter for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Rema RamanEpstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.

Funding

The Alzheimer's Clinical Trial Consortium - Down Syndrome Network (ACTC- DSN)U24AG057437 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul S. Aisen, RONALD C PETERSEN · 2018 to 2026
$198.4M
RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's DiseaseR01AG053798 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI AISEN, PAUL S., CUMMINGS, JEFFREY L. · 2017 to 2022
$39.4M
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension StudyR01AG063689 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AISEN, PAUL S., SPERLING, REISA A. · 2019 to 2024
$30.8M
Additional private donors to Brigham and Women's Hospital, with in-kind support from Avid Radiopharmaceuticals, Cogstate, Albert Einstein College of Medicine and the Foundation for Neurologic DiseasesAmerican Heart Association 946223anonymous foundationDavis Alzheimer Prevention ProgramEli LillyFoundation for the National Institutes of HealthGHR FoundationNIA NIH HHS R01 AG053798NIA NIH HHS R01 AG063689NIA NIH HHS U19 AG010483NIA NIH HHS U19AG010483NIA NIH HHS U24 AG057437NIA NIH HHS U24AG057437the Accelerating Medicines Partnershipthe Alzheimer's Associationthe NIA U24AG053798Yugilbar Foundation
6 · The paper itself

Abstract

introductionEmpirical data capturing participants' experiences in preclinical Alzheimer's disease (AD) trials are limited. We examined participant responses on a Research Satisfaction Survey (RSS) from the Anti-Amyloid Treatment in Asymptomatic AD Study.

methodsParticipants completed the RSS at week 0, 48, 108, 168, and 240. We examined potential differences in responses by baseline participant characteristics and trial completion status.

resultsRSS scores were high, with > 90% of participants responding positively to all satisfaction items. Across timepoints, altruistic motivations were most frequently affirmed, while study design elements were most frequently disfavored. Affirmation of social motivations increased over time. Participants who responded "not satisfied" at baseline to repeating their decision to enroll had higher odds of study discontinuation than those who responded "satisfied" (1.99; 95% confidence interval [CI]:1.24, 3.19). DISCUSSION: An RSS captures participant experiences in a preclinical AD trial, can guide decisions on study design features, and may identify those at risk for loss to follow-up.

Indexed as

Alzheimer DiseasePatient SatisfactionAgedFemaleHumansMaleMotivationSurveys and Questionnairesclinical trialparticipant feedbackpreclinical ADresearch satisfaction

Identifiers

PMID42773087
PMCPMC13597467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.